Schonfeld Strategic Advisors LLC Trevi Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

  • $13.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020
SELL
$2.51 - $6.87 $148,162 - $405,529
-59,029 Closed
0 $0
Q1 2020

May 15, 2020
SELL
$1.71 - $5.87 $186,969 - $641,819
-109,339 Reduced 64.94%
59,029 $194,000
Q4 2019

Feb 14, 2020
SELL
$2.78 - $4.7 $1,228 - $2,077
-442 Reduced 0.26%
168,368 $632,000
Q3 2019

Nov 14, 2019
SELL
$4.2 - $7.79 $275,654 - $511,273
-65,632 Reduced 27.99%
168,810 $760,000
Q2 2019

Aug 14, 2019
BUY
$7.5 - $10.12 $1.76 Million - $2.37 Million
234,442 New
234,442 $1.76 Million

Others Institutions Holding TRVI

# of Institutions
94
Shares Held
57.1M
Call Options Held
136K
Put Options Held
5.4K
View Full List

About Trevi Therapeutics, Inc.

TRVI Quotes by TradingView
  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email